Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
FHCO's Cash-to-Debt is ranked higher than
100% of the 1576 Companies
in the Global Household & Personal Products industry.

( Industry Median: 0.65 vs. FHCO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
FHCO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 82.65 Max: No Debt
Current: No Debt
Equity-to-Asset 0.58
FHCO's Equity-to-Asset is ranked higher than
59% of the 1540 Companies
in the Global Household & Personal Products industry.

( Industry Median: 0.52 vs. FHCO: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
FHCO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35  Med: 0.6 Max: 0.89
Current: 0.58
-0.35
0.89
Piotroski F-Score: 2
Altman Z-Score: 0.50
Beneish M-Score: -2.69
WACC vs ROIC
10.67%
-6.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -7.29
FHCO's Operating Margin % is ranked lower than
88% of the 1561 Companies
in the Global Household & Personal Products industry.

( Industry Median: 5.68 vs. FHCO: -7.29 )
Ranked among companies with meaningful Operating Margin % only.
FHCO' s Operating Margin % Range Over the Past 10 Years
Min: -7.29  Med: 17.44 Max: 31.23
Current: -7.29
-7.29
31.23
Net Margin % -14.65
FHCO's Net Margin % is ranked lower than
91% of the 1565 Companies
in the Global Household & Personal Products industry.

( Industry Median: 3.98 vs. FHCO: -14.65 )
Ranked among companies with meaningful Net Margin % only.
FHCO' s Net Margin % Range Over the Past 10 Years
Min: -14.65  Med: 21.56 Max: 45.6
Current: -14.65
-14.65
45.6
ROE % -7.21
FHCO's ROE % is ranked lower than
88% of the 1523 Companies
in the Global Household & Personal Products industry.

( Industry Median: 8.16 vs. FHCO: -7.21 )
Ranked among companies with meaningful ROE % only.
FHCO' s ROE % Range Over the Past 10 Years
Min: -7.21  Med: 39.58 Max: 74.68
Current: -7.21
-7.21
74.68
ROA % -5.73
FHCO's ROA % is ranked lower than
88% of the 1600 Companies
in the Global Household & Personal Products industry.

( Industry Median: 3.84 vs. FHCO: -5.73 )
Ranked among companies with meaningful ROA % only.
FHCO' s ROA % Range Over the Past 10 Years
Min: -5.73  Med: 32.54 Max: 61.33
Current: -5.73
-5.73
61.33
ROC (Joel Greenblatt) % -8.53
FHCO's ROC (Joel Greenblatt) % is ranked lower than
88% of the 1587 Companies
in the Global Household & Personal Products industry.

( Industry Median: 13.34 vs. FHCO: -8.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FHCO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8.53  Med: 49.59 Max: 166.5
Current: -8.53
-8.53
166.5
3-Year Revenue Growth Rate -11.30
FHCO's 3-Year Revenue Growth Rate is ranked lower than
85% of the 1341 Companies
in the Global Household & Personal Products industry.

( Industry Median: 2.50 vs. FHCO: -11.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
FHCO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -54  Med: 1.9 Max: 21.2
Current: -11.3
-54
21.2
3-Year EBITDA Growth Rate -30.90
FHCO's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 1162 Companies
in the Global Household & Personal Products industry.

( Industry Median: 5.30 vs. FHCO: -30.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
FHCO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -29.3 Max: 239.1
Current: -30.9
0
239.1
3-Year EPS without NRI Growth Rate -72.90
FHCO's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 1041 Companies
in the Global Household & Personal Products industry.

( Industry Median: 5.40 vs. FHCO: -72.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
FHCO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -72.9  Med: -6.65 Max: 188.4
Current: -72.9
-72.9
188.4
GuruFocus has detected 4 Warning Signs with The Female Health Co $FHCO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FHCO's 10-Y Financials

Financials (Next Earnings Date: 2017-07-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FHCO Guru Trades in Q1 2016

Jim Simons 594,000 sh (+3.39%)
Charles Brandes 14,331 sh (unchged)
» More
Q2 2016

FHCO Guru Trades in Q2 2016

Charles Brandes 14,331 sh (unchged)
Jim Simons 545,200 sh (-8.22%)
» More
Q3 2016

FHCO Guru Trades in Q3 2016

Charles Brandes Sold Out
Jim Simons 457,200 sh (-16.14%)
» More
Q4 2016

FHCO Guru Trades in Q4 2016

Jim Simons 439,500 sh (-3.87%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:FHCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Consumer Packaged Goods » Household & Personal Products    NAICS: 326299    SIC: 3069
Compare:NAS:SUMR, OTCPK:PNAT, AMEX:CAW, NAS:MTEX, OTCPK:SLGD, NAS:OBCI, OTCPK:AXHLF, OTCPK:SWSH, OTCPK:FTCY, OTCPK:MYHI, OTCPK:NUGN, OTCPK:SPCO, OTCPK:BEUT, OTCPK:SKVI, OTCPK:BMXC, OTCPK:EHSK, OTCPK:PURE, OTCPK:DSKX, OTCPK:KATY, OTCPK:EEIG » details
Traded in other countries:FMW.Germany,
Headquarter Location:USA
The Female Health Co is a pharmaceutical and medical device company. The company is focus on the development and commercialization of pharmaceuticals that qualify for the Food and Drug Administration's 505(b)(2) and 505(b)(1) regulatory approval pathway.

The Female Health Co is a pharmaceutical and medical device company. The Company is focus on the development and commercialization of pharmaceuticals that qualify for the Food and Drug Administration's 505(b)(2) regulatory approval pathway as well as the 505(b)(1) pathway. It does business both as Veru Healthcare and as The Female Health Company. The Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology. The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business. This division markets the Female Condom to entities, including ministries of health, government health agencies, U.N. agencies, and nonprofit organizations.

Top Ranked Articles about The Female Health Co

The Female Health Company / Veru Healthcare Announces Successful Stage 1 of the Clinical Trial to Evaluate Bioequivalence Between Tamsulosin DRS and FLOMAX®
The Female Health Company / Veru Healthcare Names Robert Getzenberg, Ph.D., as Executive Vice President of Clinical Development
The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing Tamsulosin DRS with FLOMAX®

Stage 1 of Clinical Trial Designed to Select Formulation; NDA Filing Under the 505(b)(2) Regulatory Pathway Late 2017 / Early 2018 And Approval Expected by Mid to Late 2018
MIAMI, March 09, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced that it has initiated Stage 1 of a bioequivalence (BE) clinical trial designed to select the optimal formulation of its proprietary Tamsulosin Delayed Release Sachet (DRS) product. Tamsulosin DRS is a new, slow release oral powder formulation that addresses the large patient population of men with benign prostatic hyperplasia (BPH) that have difficulty swallowing tablets or capsules.
Stage 1 of the trial compares two formulations of Tamsulosin DRS to determine the optimal formulation in terms of bioequivalence to FLOMAX® and to determine whether the formulation has a food effect. The goal is to have Stage 1 clinical trial results completed by April 2017.Assuming successful Stage 1 data, Stage 2 of the clinical trial will test the selected formulation from Stage 1 in a larger number of subjects versus FLOMAX®. The goal is to have Stage 2 of the clinical trial completed by late May 2017. Stability data is also being collected for the commercial manufactured drug batches to allow an anticipated NDA filing late 2017 / early 2018. The expected NDA approval would be sometime in mid to late 2018.“The initiation of the bioequivalence clinical study represents a very important milestone in the advancement of Tamsulosin DRS, as well as in the progression of our pipeline,” said Mitchell Steiner, M.D., President and Chief Executive Officer of The Female Health Company / Veru Healthcare. “We believe the unique attributes of Tamsulosin DRS may have substantial advantages over FLOMAX®, especially in the long-term care setting, and could improve patient compliance. Based on our pre-IND meeting in August 2016, FDA indicated that this bioequivalence trial would be acceptable means of proceeding under the 505(b)(2) regulatory pathway.”About Tamsulosin DRS for the Treatment of BPH
Overview- Tamsulosin DRS is a new powder-like formulation containing the active pharmaceutical ingredient in FLOMAX® (tamsulosin HCI) capsules which is a commonly used medicine for the treatment of BPH, also known as enlargement of the prostate. FLOMAX® is indicated for the treatment of BPH. Tamsulosin is a selective alpha1 blocker specific to receptors located in prostate and bladder smooth muscle. Symptoms associated with BPH occur because of increased prostate and bladder smooth muscle leading to constricted urinary flow, urinary retention, urinary infection, kidney damage and a life threatening blood infection called urosepsis. Blocking these receptors relaxes smooth muscle resulting in improved urinary flow and reduction of BPH symptoms. As stated in the FDA package insert, FLOMAX® capsules should not be crushed, chewed or opened, because they cannot be reliably absorbed into the bloodstream. Men with high FLOMAX® drug levels in their bloodstream are placed at risk for postural hypotension (sudden drop in blood pressure upon standing that can lead to fainting). Tablets and capsules are problematic for 15% of men over the age of 60 who have difficulty swallowing tablets and capsules and the up to 60% of men in long term facilities who have difficulty swallowing tablets and capsules because of certain medical conditions, including degenerative neurological diseases like Parkinson’s or having suffered a stroke. Not being able to take alpha1 blockers for BPH because of difficulty swallowing tablets and capsules, may lead to increased risk of acute urinary retention, urinary catheterization, urosepsis and death. Because Tamsulosin DRS is a new proprietary powder-like formulation containing the active pharmaceutical ingredient in FLOMAX®, it would provide a more convenient and reliable way to deliver therapeutic levels of tamsulosin to men who have difficulty swallowing tablets and capsules.Market- The initial marketing plan will target men in long term care facilities and men in the community that have difficulty swallowing tablets and capsules. Initially, a sales force is not required for this product as pharmacists and physicians have the ability to identify and to provide the appropriate formulation of tamsulosin for a patient who has BPH and difficulty swallowing tablets and capsules. Based on IMS data, FLOMAX® and generic tamsulosin sales from March 2014 to March 2015 were $3.48 billion in the U.S. The U.S. market for all alpha blockers for BPH is estimated to be $4.5 billion annually per IMS. Men in long term care or nursing homes have up to a 60% prevalence of swallowing difficulties and account for about 13% of total tamsulosin sales, whereas over 15% of men over 60 years of age in the general population have difficulty swallowing tablets and capsules.About The Female Health Company / Veru Healthcare
The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway.  The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows:Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.
 Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom® in the consumer health products sector and PREBOOST® medicated individual wipe, which is a male genital desensitizing drug product that helps in the prevention of premature ejaculation.
 The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business.  This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.More information about the Female Health Company and its products can be found at www.femalehealth.com, www.veruhealthcare.com and www.femalecondom.org.  For corporate and investor-related information about the Company, please visit www.FHCinvestor.com."Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.  Forward-looking statements in this release include statements relating to the expected timing for BE trails and an NDA filing for Tamsulosin DRS and the potential competitive advantages of Tamsulosin DRS.  These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release.  The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements.  Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following:  product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations; risks related to the development of the Company's product portfolio, including clinical trials, regulatory approvals and time and cost to bring to market; many of the Company's products are at an early stage of development and the Company may fail to successfully commercialize such products; risks related to intellectual property, including licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay or restructuring; a governmental tender award indicates acceptance of the bidder's price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; risks related to the costs and other effects of litigation; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2016.  These documents are available on the "SEC Filings" section of our website at www.veruhealthcare.com/investors

Contact:
Kevin Gilbert     312-366-2633

Read more...
The Female Health Company / Veru Healthcare to Host Investor Conference Call on Thursday, March 9th

MIAMI, March 03, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced that it will host a conference call to update investors on the Company’s product commercialization and drug development progress on Thursday, March 9, 2017 at 10:30 a.m. Eastern Time (ET).
The conference call will be available to interested parties by dialing 1-877-883-0383 from the U.S. or 1-412-902-6506 from international locations, participant entry number for all 9649925.  A replay of the conference call will be available beginning on Tuesday, March 14, 2017 through Tuesday, March 21, 2017, by dialing 1-877-344-7529 (international callers dial 1-412-317-0088) and entering the replay access code 10102781.  After Tuesday, March 21, 2017, the replay of the call will be available on the Company’s website at www.fhcinvestor.com. About The Female Health Company / Veru Healthcare
The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway.  The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows: Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.
 Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom® in the consumer health products sector and PREBOOST® medicated individual wipes, which are a male genital desensitizing drug product that helps in the prevention of premature ejaculation.
 The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business.  This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. More information about The Female Health Company and its products can be found at www.femalehealth.com, www.veruhealthcare.com and www.femalecondom.org.  For corporate and investor-related information about the Company, please visit www.FHCinvestor.com.
Contact:
Kevin Gilbert: 312-366-2633

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.92
FHCO's PB Ratio is ranked higher than
76% of the 1512 Companies
in the Global Household & Personal Products industry.

( Industry Median: 1.75 vs. FHCO: 0.92 )
Ranked among companies with meaningful PB Ratio only.
FHCO' s PB Ratio Range Over the Past 10 Years
Min: 0.67  Med: 8.27 Max: 19.03
Current: 0.92
0.67
19.03
PS Ratio 1.77
FHCO's PS Ratio is ranked lower than
66% of the 1516 Companies
in the Global Household & Personal Products industry.

( Industry Median: 1.07 vs. FHCO: 1.77 )
Ranked among companies with meaningful PS Ratio only.
FHCO' s PS Ratio Range Over the Past 10 Years
Min: 1.01  Med: 4.57 Max: 9.45
Current: 1.77
1.01
9.45
EV-to-EBIT -23.05
FHCO's EV-to-EBIT is ranked lower than
99.99% of the 1680 Companies
in the Global Household & Personal Products industry.

( Industry Median: 16.43 vs. FHCO: -23.05 )
Ranked among companies with meaningful EV-to-EBIT only.
FHCO' s EV-to-EBIT Range Over the Past 10 Years
Min: -714.6  Med: 26.2 Max: 361.4
Current: -23.05
-714.6
361.4
EV-to-EBITDA -34.90
FHCO's EV-to-EBITDA is ranked lower than
99.99% of the 1719 Companies
in the Global Household & Personal Products industry.

( Industry Median: 12.42 vs. FHCO: -34.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
FHCO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.2  Med: 24.6 Max: 244.4
Current: -34.9
-38.2
244.4
Shiller PE Ratio 4.28
FHCO's Shiller PE Ratio is ranked higher than
95% of the 264 Companies
in the Global Household & Personal Products industry.

( Industry Median: 28.51 vs. FHCO: 4.28 )
Ranked among companies with meaningful Shiller PE Ratio only.
FHCO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.5  Med: 25.87 Max: 502
Current: 4.28
3.5
502
Current Ratio 3.46
FHCO's Current Ratio is ranked higher than
83% of the 1427 Companies
in the Global Household & Personal Products industry.

( Industry Median: 1.60 vs. FHCO: 3.46 )
Ranked among companies with meaningful Current Ratio only.
FHCO' s Current Ratio Range Over the Past 10 Years
Min: 0.53  Med: 2.86 Max: 7.1
Current: 3.46
0.53
7.1
Quick Ratio 2.88
FHCO's Quick Ratio is ranked higher than
85% of the 1427 Companies
in the Global Household & Personal Products industry.

( Industry Median: 1.08 vs. FHCO: 2.88 )
Ranked among companies with meaningful Quick Ratio only.
FHCO' s Quick Ratio Range Over the Past 10 Years
Min: 0.24  Med: 2.37 Max: 5.97
Current: 2.88
0.24
5.97
Days Inventory 107.51
FHCO's Days Inventory is ranked lower than
74% of the 1460 Companies
in the Global Household & Personal Products industry.

( Industry Median: 63.56 vs. FHCO: 107.51 )
Ranked among companies with meaningful Days Inventory only.
FHCO' s Days Inventory Range Over the Past 10 Years
Min: 32.87  Med: 57.26 Max: 88.54
Current: 107.51
32.87
88.54
Days Sales Outstanding 178.68
FHCO's Days Sales Outstanding is ranked lower than
95% of the 1148 Companies
in the Global Household & Personal Products industry.

( Industry Median: 38.13 vs. FHCO: 178.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
FHCO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.41  Med: 86.35 Max: 177.74
Current: 178.68
27.41
177.74
Days Payable 61.28
FHCO's Days Payable is ranked higher than
62% of the 1023 Companies
in the Global Household & Personal Products industry.

( Industry Median: 45.59 vs. FHCO: 61.28 )
Ranked among companies with meaningful Days Payable only.
FHCO' s Days Payable Range Over the Past 10 Years
Min: 15.21  Med: 26.51 Max: 45.18
Current: 61.28
15.21
45.18

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
FHCO's 3-Year Dividend Growth Rate is ranked lower than
86% of the 677 Companies
in the Global Household & Personal Products industry.

( Industry Median: 4.00 vs. FHCO: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
FHCO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 20.1
Current: -100
0
20.1
5-Year Yield-on-Cost % 3.52
FHCO's 5-Year Yield-on-Cost % is ranked higher than
69% of the 2022 Companies
in the Global Household & Personal Products industry.

( Industry Median: 2.27 vs. FHCO: 3.52 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
FHCO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.71  Med: 3.51 Max: 7.45
Current: 3.52
0.71
7.45
3-Year Average Share Buyback Ratio -0.40
FHCO's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 698 Companies
in the Global Household & Personal Products industry.

( Industry Median: -1.90 vs. FHCO: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FHCO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.9  Med: -9.45 Max: -0.4
Current: -0.4
-34.9
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 4.31
FHCO's Price-to-Tangible-Book is ranked lower than
77% of the 1418 Companies
in the Global Household & Personal Products industry.

( Industry Median: 1.91 vs. FHCO: 4.31 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FHCO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.97  Med: 9 Max: 745
Current: 4.31
0.97
745
Price-to-Intrinsic-Value-Projected-FCF 0.45
FHCO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 659 Companies
in the Global Household & Personal Products industry.

( Industry Median: 1.57 vs. FHCO: 0.45 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
FHCO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.4  Med: 3.29 Max: 38.5
Current: 0.45
0.4
38.5
Price-to-Median-PS-Value 0.38
FHCO's Price-to-Median-PS-Value is ranked higher than
97% of the 1320 Companies
in the Global Household & Personal Products industry.

( Industry Median: 1.15 vs. FHCO: 0.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FHCO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.85 Max: 3.79
Current: 0.38
0.12
3.79
Earnings Yield (Greenblatt) % -4.34
FHCO's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1947 Companies
in the Global Household & Personal Products industry.

( Industry Median: 5.41 vs. FHCO: -4.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FHCO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 3.6 Max: 24.3
Current: -4.34
0.3
24.3
Forward Rate of Return (Yacktman) % 3.71
FHCO's Forward Rate of Return (Yacktman) % is ranked lower than
56% of the 771 Companies
in the Global Household & Personal Products industry.

( Industry Median: 5.68 vs. FHCO: 3.71 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
FHCO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.4  Med: 18 Max: 74.3
Current: 3.71
-0.4
74.3

More Statistics

Revenue (TTM) (Mil) $17.14
EPS (TTM) $ -0.08
Beta1.41
Short Percentage of Float0.84%
52-Week Range $0.72 - 1.65
Shares Outstanding (Mil)31.34
» More Articles for NAS:FHCO

Headlines

Articles On GuruFocus.com
The Female Health Company / Veru Healthcare Announces Successful Stage 1 of the Clinical Trial to Ev Apr 12 2017 
The Female Health Company / Veru Healthcare Names Robert Getzenberg, Ph.D., as Executive Vice Presid Apr 11 2017 
The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing Tam Mar 09 2017 
The Female Health Company / Veru Healthcare to Host Investor Conference Call on Thursday, March 9th Mar 03 2017 
5-year lows: PICO Holdings Inc, Electro Scientific Industries, Dawson Geophysical Co, and Female Hea Feb 21 2015 
5-year lows: Walter Energy, HHGregg Inc, Dawson Geophysical Co, and Female Health Co. Sep 22 2014 
Weekly 3-Year Low Highlights: GES, QLGC, NPK, PHMD, FHCO Aug 31 2014 
5-year lows: NGP Capital Resources Company, API Technologies Corp, Female Health Co, and Cal Dive In Aug 04 2014 
5-year lows: Layne Christensen Co, Hansen Medical Inc, API Technologies Corp, and Female Health Co. Jul 27 2014 
4 Stocks Raising Dividends and Expectations Apr 01 2013 

More From Other Websites
This Biotech Small-Cap Has Big Ambitions Apr 26 2017
The Female Health Company / Veru Healthcare Announces Successful Stage 1 of the Clinical Trial to... Apr 12 2017
The Female Health Company / Veru Healthcare Names Robert Getzenberg, Ph.D., as Executive Vice... Apr 11 2017
ETFs with exposure to The Female Health Co. : April 5, 2017 Apr 05 2017
The Female Health Co. :FHCO-US: Earnings Analysis: Q1, 2017 By the Numbers : March 10, 2017 Mar 10 2017
The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing... Mar 09 2017
The Female Health Company / Veru Healthcare to Host Investor Conference Call on Thursday, March 9th Mar 03 2017
The Female Health Company / Veru Healthcare Names Matthew Gosnell, Ph.D., as Senior Vice President... Feb 16 2017
The Female Health Company / Veru Healthcare Reports Fiscal 2017 First-Quarter Financial Results Feb 09 2017
ETFs with exposure to The Female Health Co. : January 20, 2017 Jan 20 2017
The Female Health Co. :FHCO-US: Earnings Analysis: 2016 By the Numbers : December 16, 2016 Dec 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)